Lyme disease
Therapeutic area
Infectious Disease
Rare disease
Yes
- Definition
- Lyme disease (named after the towns in the USA where the disease was first identified) is a bacterial infection caused by Borrelia burgdorferi.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Lyme disease
- Therapeutic area
- Infectious Disease
- Lyme disease
- Borrelia
- Borrelia burgdorferi infection
- Borreliella burgdorferi caused disease or disorder
- Borreliella burgdorferi disease or disorder
- Borreliella burgdorferi infectious disease
- Lyme borreliosis
- Lyme disease
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Moderate
- MONDO ID
- MONDO:0019632
- Parent condition
- MONDO:0000314
Related records
Broader conditions (10)
- Bacterial infectious disease
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Primary bacterial infectious disease
- Spirochaetales infections
- Tick-borne infectious disease
- Vector-borne disease
Trials (94)
- A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
- A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
- A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France
- A Multicenter Study to Evaluate a Borrelia Diagnostic Test in Subjects With Early Stage or Late Stage Lyme Disease
- A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
- A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Lyme Disease
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease
- A School-Based Intervention to Reduce Lyme Disease
- A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
- A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)
- A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults
- A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine
- Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis
- An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
- Analysis of Lyme Disease Lesions
- Anti-phospolipid Antibodies in Lyme Borreliosis
- Antibiotic Treatment of Multiple Erythema Migrans
- Biomarker Study of Previously Treated Lyme Disease Volunteers in Comparison to Healthy Volunteers
Drugs in development (6)
- Ceftriaxone Phase 3
- Doxycycline Phase 3
- Permethrin Phase 3
- Psilocybin Phase 1
- Sodium chloride Phase 3
- Tetracycline Phase 2
Other linked drugs (1)
- Demeclocycline